Ropes & Gray counseled Eloxx Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, in its completed acquisition of Sevion Therapeutics, Inc. The combined company will be known as Eloxx Pharmaceuticals, Inc. and will focus on advancing the clinical development of ELX-02, a disease-modifying therapy for genetic diseases caused by nonsense mutations. Eloxx is a portfolio company of Pontifax, one of Israel’s leading life science venture funds. The transaction closed on December 19.
The Ropes & Gray team was lead by partner and co-head of the firm’s mergers and acquisitions practice Carl Marcellino, from the firm’s New York office.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.